

# Acute Promyelocytic Leukemia

Although acute promyelocytic leukemia (APL) is relatively rare, it is a medical emergency that is important for the intensivist to recognize. APL is a variant of acute myeloid leukemia (AML) that is highly curable (80-90%) but carries a significant early mortality risk due to bleeding and thrombotic complications. Outcomes can be improved through early recognition, prompt initiation of definitive treatment, and aggressive management of coagulopathy.

## Pathologic Diagnosis

**Definitive diagnosis** = Presence of PML-RARA fusion gene and/or the t(15;17) translocation.

While awaiting molecular confirmation, a presumptive diagnosis of APL can often be made based on the presence of atypical promyelocytes on the peripheral smear.

- Hypergranular variant: Granular cytoplasm visible on light microscopy, auer rods may be present
- Microgranular variant: Granules not visible on light microscopy




Image credit: American Society of Hematology Image Bank

## Clinical Presentation

### Presenting Symptoms:

May be variable depending on the extent of cytopenia and include the following:

- **Systemic symptoms:** Fever, generalized malaise, fatigue, weakness
- **Bleeding complications:** Easy bruising, petechiae, epistaxis, gingival bleeding, menorrhagia

### WBC Count:

Patients frequently present with a low WBC with few promyelocytes in the peripheral circulation. If presenting WBC is  $> 10 \times 10^9/L$ , patients are at a higher risk of complications and early death.

### Key Features:

Patients often present with evidence of hyperfibrinolysis and DIC:

- Thrombocytopenia and schistocytes
- Elevated INR and PTT
- Low fibrinogen

Life-threatening bleeding complications including intracranial or pulmonary hemorrhage may occur.

Thrombosis may also be observed

## Management

1

### **Start Treatment Immediately:**

Therapy should be started ASAP, even if a definitive diagnosis has not been made. Your local Hematologist as well as the closest cancer center with a leukemia program should be contacted urgently.

Treatment = all-trans retinoic acid (ATRA) plus either arsenic trioxide (ATO) or anthracycline-based chemotherapy.

2

### **Coagulopathy is a life-threatening emergency:**

Patients must be closely monitored:

- Check CBC, INR/PTT, fibrinogen Q6H

Administer blood products as needed to meet the following targets:

- Fibrinogen  $> 1.5g/L$ , INR  $< 1.5$ , and platelets  $> 20$  to  $30 \times 10^9/L$  ( $> 50 \times 10^9/L$  in bleeding patients).

3

### **Recognize differentiation syndrome:**

After treatment is started, promyelocytes rapidly mature leading to a systemic inflammatory response characterized by the following:

- Onset is usually within 2 weeks of chemotherapy
- Fever, hypotension, hypoxemia, lung infiltrates, pleural/pericardial effusions, ascites, elevated bilirubin, and acute kidney injury

Differentiation syndrome may occur in up to 25% of patients. When suspected, treatment with steroids should be initiated:

- Dexamethasone 10mg BID
- Low-dose prophylactic dexamethasone (2.5mg BID) may be considered for patients with starting WBC  $> 5 \times 10^9$  in consultation with the treating Oncologist